New Launch10 April 2026 at 02:31 pm
Lupin Launches Dapagliflozin Tablets in US
AI Summary
Lupin Limited announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States on April 10, 2026. This launch follows the U.S. FDA's approval of its Abbreviated New Drug Application (ANDA), confirming bioequivalence to Farxiga®. Dapagliflozin is a widely used medication for diabetes and heart failure. This strategic move expands Lupin's presence in the anti-diabetic and cardiovascular therapy areas in the crucial U.S. market and is expected to contribute to its generic portfolio growth and market share.
Key Highlights
- Lupin launched Dapagliflozin Tablets in the US market.
- Product is a generic version of Farxiga® (5 mg and 10 mg).
- Received U.S. FDA approval for its Abbreviated New Drug Application.
- Strengthens Lupin's presence in the US anti-diabetic segment.
- Expected to boost generic portfolio and market share.
LUPINPharmaceuticals
LUPIN LTD.Price Impact